Estrella Immunopharma Inc has made significant strides in advancing its pipeline of cancer therapies through strategic developments, including securing $3.35 million in funding and expanding its clinical trial infrastructure.

Estrella Immunopharma Inc, a preclinical-stage biopharmaceutical company, is at a critical juncture as it navigates financial uncertainty and high industry risks in its pursuit of groundbreaking CD19 and CD22-targeted T-cell therapies.